Guideline-Based Medication Selection

The ADA/EASD Cardiorenal-First Framework

Historically, oral diabetes therapy followed a strict, incremental stepladder: start metformin, then add a second oral agent chosen mostly by its A1C-lowering potency, then a third, then insulin. Current ADA Standards of Care and the ADA/EASD consensus approach replace that ladder with a framework that asks, before considering glycemic potency, whether the person has an established indication for cardiorenal protection.

Step 1: Screen for Cardiorenal Risk, Independent of A1C

For anyone with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), current guidance recommends starting or adding a GLP-1 receptor agonist with proven cardiovascular benefit (for ASCVD) or an SGLT2 inhibitor with proven heart-failure or renal benefit — regardless of baseline A1C, and independent of whether the person is already taking metformin. This is a fundamental shift from older algorithms: the cardiorenal-protective agent is selected because of the comorbidity itself, not because of glycemic need. This organizing theme is sometimes described using the term cardiovascular-kidney-metabolic (CKM) health.

• ASCVD or high ASCVD risk → favor a GLP-1 receptor agonist (or dual GIP/GLP-1 agonist) with demonstrated cardiovascular outcome benefit, or an SGLT2 inhibitor.
• Heart failure (particularly HFrEF, with growing evidence in HFpEF) → favor an SGLT2 inhibitor.
• CKD (with or without albuminuria) → favor an SGLT2 inhibitor with demonstrated renal outcome benefit; a non-steroidal mineralocorticoid receptor antagonist and/or a GLP-1 receptor agonist may be added per current CKD-specific guidance.

Step 2: Weigh Glycemic Efficacy, Weight Effect, Hypoglycemia Risk, and Cost

Once cardiorenal indications are addressed — or if none are present — agent selection is individualized across several additional dimensions.

Early Combination Therapy

Older algorithms added a second agent only after metformin monotherapy failed to control glucose. The 2022 ADA/EASD consensus report explicitly supports considering early combination therapy — starting two agents together at diagnosis or soon after — based on the perceived need for additional glycemic efficacy or cardiorenal protection, rather than waiting for monotherapy to fail. The rationale is that starting combination therapy earlier extends the time to treatment failure and reaches glycemic and cardiorenal goals faster than the traditional sequential stepladder, particularly for people presenting with a markedly elevated A1C or an established cardiorenal indication at diagnosis.

Applying the Framework

Metformin remains a reasonable foundation for most people without a cardiorenal indication because of its efficacy, safety, weight neutrality, and low cost, but it is no longer a mandatory first step before a cardioprotective agent is added — a person with ASCVD or CKD should receive a GLP-1 receptor agonist or SGLT2 inhibitor even if metformin alone has not reached maximum dose, and even if A1C is already at or near target. When additional glycemic efficacy is still needed, the CDCES helps the care team select from the remaining classes by weighing the four factors above (efficacy, weight, hypoglycemia risk, cost) against the individual's values, comorbidities, and life circumstances — for example, avoiding sulfonylureas in someone with hypoglycemia unawareness or an unpredictable schedule, or avoiding TZDs in someone with heart failure.

The Educator's Role in Shared Decision-Making

Because most people manage multiple chronic conditions simultaneously, medication selection is rarely made by a prescriber in isolation. The CDCES contributes disease-specific knowledge — how a person's actual eating pattern, activity, and monitoring habits interact with a given agent's dosing schedule and side-effect profile — identifies barriers (injection anxiety, cost, GI tolerance, cognitive or literacy factors), and reinforces adherence counseling once a regimen is selected. Reassessing medication fit belongs in every follow-up visit: weight trend, hypoglycemia frequency, GI tolerance, and renal function can all shift the risk-benefit balance for a given class over time, so the framework above should be reapplied at each visit, not just at the initial choice.

Common Exam Traps

• Do not assume metformin must always be started before a GLP-1 receptor agonist or SGLT2 inhibitor — cardiorenal indications override the traditional stepladder.
• An A1C at goal is not a reason to withhold a cardioprotective agent from someone with ASCVD, heart failure, or CKD — the indication driving the choice is the comorbidity, not glycemic need.
• "Lowest cost" and "most potent" are not the only selection criteria the exam tests — hypoglycemia risk and weight effect are equally emphasized decision factors.